Netherlands Medicines Evaluation Board says no ‘relevant differences’ between biosimilars, reference products

By Zachary Brennan contact

- Last updated on GMT

Related tags: Medicine

Netherlands Medicines Evaluation Board says no ‘relevant differences’ between biosimilars, reference products
The Medicines Evaluation Board (MEB) of the Netherlands has updated its position about biosimilars, saying the relatively new products “have been proven to have no relevant differences compared to an innovator biological medicinal product as far as quality, safety and efficacy are concerned.”

Since 2010 -- when the MEB adopted its first position on biosimilars, which was that patients “must be kept on a biological medicinal product as much as possible if they respond well to it clinically​” – the board has since conducted a study of the most recent literature and experiences in the evaluation of biosimilars and deemed “that this strict condition is no longer valid​.”

There is enough evidence to support the use of biosimilars in clinical practice, provided this occurs with caution and under certain conditions​,” the MEB, which assesses and monitors the efficacy, risks and quality of human drugs, says in its new position statement​.
The exchange between biological medicines -- “regardless of whether they are innovator products or biosimilar medicinal products​” -- is now permitted, which essentially deems them to be interchangeable, but only if adequate clinical monitoring is performed and the patient is properly informed, the board says.

The Medicines Evaluation Board has also taken some other positions on biosimilars, including that new patients can be treated with a biosimilar “right away​,” though “uncontrolled exchange between biological medicinal products (regardless of whether they are innovator products or biosimilar medicinal products) must be avoided. In other words, a patient must receive adequate clinical monitoring and clear instructions​,” the board says.

In addition, if a patient is treated with a biosimilar, detailed product and batch information must be recorded in the patient file to guarantee the traceability of the product in the event of problems.

The MEB emphasises “the need for the treating physician and the (hospital) pharmacist to be involved in the decision to switch from one biosimilar medicinal product to another, so that an informed decision can be taken. Cooperation in the area of pharmacovigilance (efficacy and adverse events) is essential​.”

The MEB also emphasises the importance of intercalating the use of - for example - the new generation of biosimilar therapeutic antibodies in registry studies and performing intensive monitoring and practice-based research.

Related news

Show more

Related products

show more

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Blazar™ Platform: Rodent Virus Panel

Blazar™ Platform: Rodent Virus Panel

Viral Safety for mAb: Prevent, Detect, Remove | 16-Nov-2020 | Technical / White Paper

We have a long history of developing innovative molecular technologies for cell line characterization and lot release testing for the biopharmaceutical...

Monitoring SARS-CoV-2 interaction with ACE2

Monitoring SARS-CoV-2 interaction with ACE2

Take the Right Path Upstream with MilliporeSigma | 02-Nov-2020 | Technical / White Paper

In this technical note, we investigate the interactions between the following: The spike glycoprotein binding with ACE2, Spike glycoprotein and anti-spike...

Related suppliers

Follow us

Products

View more

Webinars